DBV Technologies S.A.
DBVTHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframeDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. With a market capitalization of $1.12B, it sits in small-cap territory. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Market Cap
$1.12B
Beta
-0.24
P/E (TTM)
—
P/E (Fwd)
-38.92
EPS (TTM)
$-4.50
EPS (Fwd)
$-0.49
ROE
-158.9%
ROA
-66.4%
Cash
$229.2M
Total Debt
$6.1M
Free CF
-$87.2M
52W Change
127.4%
Annual Financials
Cash vs Debt
DBV Technologies S.A. holds $229.2M in cash against $6.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$87.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -158.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
DBVT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, DBVT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence DBV Technologies S.A.'s trajectory.